期刊文献+

口服小分子靶向抗肿瘤药物的不良反应及防治措施 被引量:9

Prevention and treatments for adverse drug reactions of oral small molecular targeting drugs
原文传递
导出
摘要 目前已有多个口服小分子靶向抗肿瘤药物在我国上市,文中对近年相关文献进行归纳、分析,从皮肤系统、消化系统、循环系统、血液系统等方面综述此类药物的不良反应和防治措施,为临床医生安全合理用药及临床药师进行药学服务提供参考。 A number of oral small molecular targeting drugs have been already approved by State Food and Drug Administration of China. This review summarized and analyzed the prevention and treatments of adverse drug reactions for this kind of agents, including those in dermal, digestive, circulatory and hematological systems. The goal is to supply references for more rational use, and for clinical pharmacists to pharmaceutical care.
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第18期1807-1811,1816,共6页 Chinese Journal of New Drugs
关键词 靶向 抗肿瘤药物 不良反应 targeting antitumor drugs adverse drug reactions (ADR)
  • 相关文献

参考文献30

  • 1Cancer Therapy Evaluation Program, Common terminology criteria for adverse events Version 3.0, DCTD, NCI, NIH. , 2003 [ EB/ OL]. [2008 - 12 - 10]. http://ctep, cancer, gov.
  • 2RANSON M, HAMMOND LA, FERRY D, et al. ZD1839, a seective oral epidermal growth factor receptortyrosine kinase inhibi tot, is well tolerated and active in patients with solid, malignan// tumors : results of a phase Ⅰ trial[ J ]. J Clin Oncol,2002,20 ( 9 ) 2240 - 2250.
  • 3HIDALGO M, SIU LL, NEMUNAITIS J ,et al. Phase Ⅰ and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies[ J]. J Clin Oncol,2001,19 ( 13 ) :3267 - 3279.
  • 4JACOT W, BESSIS D, JORDA E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours[ J]. Br J Dermatol,2004,151 ( 1 ) :238 -241.
  • 5PEREZ-SOLER R, CHACHOUA A, HAMMOND LA,et al. Determinants of tumor response and survival with erlotinib in patients with none small-cell lung cancer[J]. J Clin Oncol, 2004, 22 ( 16 ) :3238 - 3247.
  • 6VAN DOORN R, KIRTSCHIG G, SCHEFFER E,et al. Follicular and epidermal alterations in patients treated with ZD1839 (lressa), an inhibitor of the epidermal growth factor receptor [ J ]. Br J Dermatol,2002, 147 ( 3 ) : 598 - 601.
  • 7SHAH NT, KRIS MG, PAO W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib [ J ]. J Clin Oncol,2005,23 (1) : 165 - 174.
  • 8CLARK JW, EDER JP, RYAND. et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced refractory solid tumors [ J ]. Clin Cancer Res, 2005, 11 ( 15 ) :5472 - 5480.
  • 9ALBANELL J, ROJO F, AVERBUCH S, et al. Pharmacodyna- mic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition [ J ]. J Clin Oncol,2002, 20(1):110-124.
  • 10CHU D, LACOUTURE ME, FILLOS T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis [ J ]. Acta Oncol,2007,47 ( 2 ) : 176 - 186.

同被引文献107

引证文献9

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部